Source of Support: None, Conflict of Interest: None
Conventional 12 or 18-month anti-tuberculous drug regimens (SH-B/W, STH + TH) continue to be primary treatment schedules in majority of the patients in the District Tuberculosis Programme in India. Pulmonary tuberculosis patients falled to one of these regimens were retreated with two drug formulations, i.e., 1ERZ + 11E2 R2 and 2ERZ + 10 E2 R2. Sputum conversion rates at the end of two months treatment were 91% and 92% respectively. The relapse rates had been 5.2% and 4.8% respectively at the end of one year follow-up. Thus, Pyrazinmide administration (during initial intensive phase) beyond one month did not offer any additional benefit.